drug
glycopyrronium tosylate
Marketedupdated 3mo agoby $DERM Journey Medical Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying glycopyrronium tosylate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 17, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Feb 28, 2033formulationUS 10004717
- Feb 28, 2033formulationUS 10543192
- Feb 28, 2033compositionUS 10548875
- Feb 28, 2033formulationUS 8859610
- Feb 28, 2033method-of-use (U-2398)US 9259414
- Jul 18, 2030formulationUS 97441054.0y
- Dec 10, 2029formulationUS 86181603.4y
- Oct 17, 2028formulationUS 100522672.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that